Arrowhead Pharmaceuticals, Inc.(ARWR)Earnings, Financials & Key RatiosArrowhead Pharmaceuticals, Inc. (ARWR) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q2
the company's reliance on non-recurring milestone payments to cover quarterly R&D expenditures exceeding $167 million creates a high-risk liquidity profile that warrants extreme caution.
Arrowhead Pharmaceuticals, Inc. (ARWR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Arrowhead Pharmaceuticals, Inc. (ARWR) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.93vs $1.09+14.7% | $74Mvs $74M-0.1% |
| Q1 2026 | Feb 5, 2026 | $0.22vs $0.60-63.3% | $264Mvs $214M+23.4% |
| Q4 2025 | Nov 25, 2025 | $0.18vs $0.11-61.3% | $256Mvs $175M+46.3% |
| Q3 2025 | Aug 7, 2025 | $1.26vs $0.94-34.0% | $28Mvs $154M-82.0% |
Recent stock market news and headlines for Arrowhead Pharmaceuticals, Inc. (ARWR)
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). REDEMPLO is the first and only siRNA medicine authorized by the EC for adults with FCS, diagnosed either by the presence of clinical crit.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule (TRiM™) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company's clinical candidates and externa.
Key metrics vs top competitors for Arrowhead Pharmaceuticals, Inc. (ARWR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $86.97 | $12.25B | -7128.69 | 23258.15% | -0.2% | -0.47% | — | |
| $321.59 | $42.91B | 138.02 | 65.19% | 13.46% | 98.29% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — |
Arrowhead Pharmaceuticals, Inc. (ARWR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Arrowhead Pharmaceuticals, Inc. (ARWR) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Mar 20, 2026·SEC
Feb 5, 2026·SEC
Get notified when ARWR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Arrowhead Pharmaceuticals, Inc. (ARWR) stock FAQ — growth, dividends, profitability & financials explained
Arrowhead Pharmaceuticals, Inc. (ARWR) reported $622.0M in revenue for fiscal year 2025. This represents a 812028% increase from $0.1M in 1997.
Arrowhead Pharmaceuticals, Inc. (ARWR) grew revenue by 23258.2% over the past year. This is strong growth.
Arrowhead Pharmaceuticals, Inc. (ARWR) reported a net loss of $300.9M for fiscal year 2025.
Arrowhead Pharmaceuticals, Inc. (ARWR) has a return on equity (ROE) of -0.5%. Negative ROE indicates the company is unprofitable.
Arrowhead Pharmaceuticals, Inc. (ARWR) had negative free cash flow of $50.9M in fiscal year 2025, likely due to heavy capital investments.
